| __timestamp | Apellis Pharmaceuticals, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 15746000 |
| Thursday, January 1, 2015 | 6356782 | 13392000 |
| Friday, January 1, 2016 | 4303743 | 9290000 |
| Sunday, January 1, 2017 | 10463151 | 7672000 |
| Monday, January 1, 2018 | 22639184 | 15293000 |
| Tuesday, January 1, 2019 | 67046483 | 22648000 |
| Wednesday, January 1, 2020 | 139401000 | 21864000 |
| Friday, January 1, 2021 | 176771000 | 37318000 |
| Saturday, January 1, 2022 | 277163000 | 48130000 |
| Sunday, January 1, 2023 | 500815000 | 108146000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Apellis Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by over 17,000% from 2014 to 2023. In contrast, Madrigal Pharmaceuticals experienced a more modest increase of approximately 587% during the same timeframe.
This divergence highlights differing strategic approaches: Apellis's aggressive expansion and marketing efforts versus Madrigal's more conservative spending. By 2023, Apellis's SG&A expenses were nearly five times higher than Madrigal's, reflecting its broader market reach and investment in growth. Understanding these trends provides valuable insights into each company's operational priorities and market strategies.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights